Fred Aslan | BiotechTV

top of page

Aug 15, 2024

Checking in with Artiva CEO Fred Aslan after the NK cell focused company's $167 million IPO

He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is...

Using NK cell therapies for autoimmune disease and cancer with Artiva's CEO

Mar 1, 2024

Bright Minds

Using NK cell therapies for autoimmune disease and cancer with Artiva's CEO

Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Saville's Life Sciences Overview

bottom of page

Checking in with Artiva CEO Fred Aslan after the NK cell focused company's $167 million IPO

Using NK cell therapies for autoimmune disease and cancer with Artiva's CEO

Follow BiotechTV

Sponsors

Sponsor Spotlight